NCT07840924已完成2 期
The CanISleepinMS Study: Effect of Cannabidiol (CBD) on Sleep Quality in Patients With Multiple Sclerosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Insomnia Severity Index (ISI)
研究概览
简要总结
Evaluating the effect of 300 mg purified cannabidiol (CBD) on sleep quality in patients with multiple sclerosis (MS).
详细描述
The investigators conducted a series of 16 aggregated randomized, placebo-controlled N-of-1 trials to investigate the effect of purified cannabidiol (CBD) oil on nocturnal sleep quality in patients with multiple sclerosis. Each participant completed four treatment periods: two with CBD (300 mg daily) and two with placebo. The primary outcome is the insomnia severity index (ISI). Secondary outcomes included a sleep-wake diary and scores on the Checklist Individual Strength Fatigue subscale (CIS-F), Fatigue Severity Scale (FSS), and Epworth Sleepiness Scale (ESS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
It is a double blinded trial in which neither the participants nor the researcher knows when a participant receives cannabidiol or placebo.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of MS confirmed by a neurologist, based on the revised 2010 or 2017 McDonalds criteria
- •Relapsing-remitting or primary or secondary progressive MS
- •Expanded Disability Status Scale (EDSS) score <7.5
- •No relapse for at least 6 months before the screening visit
- •No changes in immunomodulating therapy stable
- •For at least 3 months before the screening visit; no changes in use of other medications used for chronic conditions for at least 6 weeks before the screening visit (e.g. anti-depressant drugs, antidiabetics)
- •Age minimally 18 years at the time of screening
- •Body Mass Index (BMI) < 35.0 kg/m2 at the moment of screening
- •Elevated levels of transaminases (ALAT, ASAT) until twice the Upper Limit of Normal (2x ULN) are allowed, as elevation of these levels is a common finding in MS patients
- •No plans to (be involved in) getting pregnant during the trial
- •No breast feeding during the trial
- •A complaint of chronic impairment of sleep quality, leading to a diagnosis of insomnia by an MS neurologist and an experienced somnologist. In this context, insomnia is defined as difficulties initiating and/or maintaining sleep or too early awakenings, despite adequate opportunity and circumstances for sleep, resulting in some form of daytime impairment. Causes include psychophysiological insomnia, insomnia due to mental disorders like depression, and insomnia secondary to other MS-related symptoms like spasticity, pain or nocturnal voidings.
- •Diagnosis will be based on fulfilment of the ICDS-3 criteria of insomnia and an ISI score of minimally 15 (threshold for clinical insomnia).
- •Continuation of pharmacological treatments will be at the discretion of the study physicians.
- •Willing and able to refrain from new, sleep-facilitating pharmacological treatments until the end of the treatment phase of the study
- •Willing and able not to use any other cannabis product until completion of the study
- •Willing and able not to use any supplement that could promote sleep (e.g. L-tryptophan,
- •valerian, melatonin) during the treatment phase of the study.
- •Continuation of non-pharmacological treatments will be at the discretion of the study physicians.
- •Willing and able to refrain from new, sleep-facilitating nonpharmaceutical interventions until the end of the treatment phase of the study. Lifestyle should be kept as stable as possible.
- •Willing and able to give informed consent
- •Willing and able to fill in a daily digital diary during the treatment phase, to send this to the study nurse or research assistant once a week, and to be contacted by the research assistant minimally twice a week during the treatment phase of the study
- •Willing and able to use the Neurokeys app (thus mobile phone) daily
- •Willing to have blood sampled at the screening visit and have another
- •two blood draws during the treatment phase of the study
- •Willing and able not to drive a car or operate machinery within 8 hours after intake of the investigational product until the end of the treatment phase of the study
- •Willing and able not to do evening/night shift work and not to cross time zones until the completion of the study
- •Willing and able to refrain from excessive use of excessive use of caffeine (> 1 cup of coffee or 1 serving of energy drink) and alcohol (> 1 serving) in the evening, 6 hours before going to bed
- •Willing and able to refrain from (products of) grapefruit, Seville oranges (used in marmalade), limes and pomelos during the treatment phase of the study
- •Willing and able to refrain from experimenting with timing and type of diet, and beverages during the treatment phase of the study. A participant's dietary intake pattern should be kept as stable as possible during the treatment phase as there are numerous dietary components other than furanocoumarins that may influence CBD bioavailability
排除标准
- •Circadian rhythm sleep-wake disorders, sleep related breathing disorders (such as moderate to severe obstructive sleep apnea, central breathing disorders during sleep, or sleep-related stridor that require prompt specific treatment), current delayed sleep phase syndrome where wake up time is regularly later than 8.00 a.m., or a sleep problem fulfilling the ICSD3 criteria of parasomnias
- •Good response to initial treatment for the assessed sleep disorder
- •Use of a benzodiazepine or other sleep medication, unless the patient has tapered off the sleep medication before the moment of inclusion
- •Liver disease or blood levels of transaminases (ALAT, ASAT) above 3x ULN, as long term administration of high doses of CBD may affect (although reversible) liver function
- •History of severe psychiatric comorbidity
- •Increased risk of suicidal thoughts or behaviour
- •History of drug or alcohol abuse
- •Known or suspected hypersensitivity to cannabinoids or to excipients of the formulation of the investigational product - almond oil
- •History of use with CBD oil prepared by pharmacy Clinical Cannabis Care
- •Structural or recreational use of a cannabinoid product < 2 months before screening
- •Whether the use of any of the following medications is a reason for exclusion will be at the discretion of the study physicians and delivery pharmacist.
- •drugs with risk of liver injury; the decision of exclusion will be made in consultation with the MS neurologists and the pharmacist that provides the CBD product.
- •drugs with risk of interaction with CBD. Data on the potential drug-CBD interactions below are based on mechanistic and clinical studies:
- •drugs of which their biotransformation is primarily dependent on the cytochrome P450 enzymes CYP2C19 and CYP3A
- •drugs that are inducers or inhibitors of enzymes of which CBD is a substrate: CYP2C19, CYP3A4.
研究组 & 干预措施
Placebo
Placebo Comparator
The investigational placebo consists of almond oil with a subtle blood orange flavor.
干预措施: Cannabidiol Oil (Drug)
Cannabidiol Oil
Experimental
The Investigational Medicinal Product consists of purified cannabidiol in almond oil.
干预措施: Cannabidiol Oil (Drug)
结局指标
主要结局
Insomnia Severity Index (ISI)
时间窗: The ISI was administered at baseline and at the end of every treatment block, measuring perceived severity of insomnia over the last two weeks (weeks 2,5,9,13,17)
The ISI is a validated tool to assess insomnia and sensitive to treatment response. The ISI is composed of seven items, each with a 5-point rating scale ranging between and to 4 (no to severe problem). Higher scores indicate worse outcomes. A total score between 0-7, 8-14, 15-21, and 22-28 is explained as no, sub threshold, moderate, and severe insomnia, respectively. A change in ISI score of 5 is considered as a clinical improvement.
次要结局
- Sleep diary - total sleep time(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- Epworth Sleepiness Scale (ESS)(At the end of every two weeks in each of 4 treatment periods (weeks 1, 2, 4, 5, 8, 9, 12, 13, 16, 17))
- Fatigue Severity Scale (FSS)(At the end of every two weeks in each of 4 treatment periods (weeks 1, 2, 4, 5, 8, 9, 12, 13, 16, 17))
- Checklist Individual Strength Fatigue subscale (CIS-F)(At the end of every two weeks in each of 4 treatment periods (weeks 1, 2, 4, 5, 8, 9, 12, 13, 16, 17))
- Keystroke dynamics(Continuously and daily during the 18-week study period.)
- Sleep diary - sleep onset latency(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- Sleep diary - number of awakenings(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- Sleep diary - sleep efficiency(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- Sleep diary - time in bed(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- Sleep diary - wake after sleep onset(Daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- NRS - fatigue(Once daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- NRS - pain(Once daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- NRS - spasticity(Once daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
- NRS - Noctural Voiding(Once daily; from enrollment to the end of treatment at 18 weeks, with an exception of wash out periods.)
研究者
Renger Witkamp
Prof.dr. Renger F. Witkamp (Emeritus Professor Nutritional Biology)
Wageningen University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and InsomniaMalignant Solid NeoplasmInsomniaNCT07565974Mayo Clinic69
尚未招募
2 期
Mechanisms of Cannabidiol and Sleep in the Context of Alcohol UseSleepAlcohol MisuseNCT07527338University of Colorado, Boulder58
招募中
不适用
Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) StudyHealthy VolunteerNCT07656350King's College London60
尚未招募
1 期
Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow TrialHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmNCT07658677Theodore Brasky PhD50
招募中
2 期
The Effect of CBD on Sleep Quality Following Late Evening ExerciseSleep QualityNCT07570472KU Leuven20